Revolutionizing Mammography Services
Volpara, a company under Lunit, is making significant strides in the enhancement of breast cancer screening. Recently, the company has secured a substantial contract with the U.S. Defense Health Agency (DHA) valued at $7.3 million over a five-year term. This initiative is focused on implementing Volpara's Patient Hub™, an advanced system that integrates mammography reporting, cancer risk assessment, and patient tracking across military health facilities.
Enhancing Breast Cancer Screening
The deployment of Volpara's Patient Hub™ aims to modernize the way healthcare providers manage breast cancer screenings for military personnel and their families. This innovative technology not only improves reporting capabilities but also streamlines risk assessment processes, which are critical in enhancing patient care.
Key Features of Patient Hub™
Key functionalities of the Patient Hub™ include comprehensive scheduling data collection, efficient risk assessment tools, and effective mammogram tracking. These features collectively ensure that providers are delivering personalized care efficiently. By automating follow-ups, reminders, and patient communications, Patient Hub™ lessens administrative workloads and enhances adherence to breast health guidelines, ultimately leading to improved early detection outcomes.
Commitment to Healthcare Excellence
During an announcement, Teri Thomas, CEO of Volpara and CBO of Lunit, emphasized the opportunity of collaborating with the Defense Health Agency. She noted that meeting the stringent security standards set by the Department of Defense is a testament to Volpara's dedication to patient care and data protection. This partnership signifies Volpara's ongoing commitment to advanced healthcare solutions that profoundly impact breast health outcomes.
Milestone for Volpara Health
This contract marks a pivotal achievement in Volpara's mission to enhance breast health via innovative technology. The company has a rich history, with generations of its mammography reporting software having been utilized by the Department of Defense since 1990. This legacy underlines the trust placed in Volpara’s solutions over the decades.
About Volpara Health
Volpara Health is dedicated to saving families from cancer through its AI-driven software designed to aid healthcare providers in assessing cancer risks and guiding personalized care decisions. With usage in over 2,000 healthcare facilities worldwide, the software touches nearly 17 million patients and supports 3 million annual cancer risk assessments, integrating seamlessly with electronic health records and imaging systems.
The focus on enhancing radiologist capabilities by enabling precise quantification of dense breast tissue and optimizing mammogram production through effective positioning, compression, and dose management has made Volpara a trusted partner among leading healthcare institutions globally. Headquartered in Wellington, New Zealand, and with an office in Seattle, Volpara continues to be at the forefront of advancing breast health.
Frequently Asked Questions
What is Volpara's Patient Hub™?
It is an advanced system that integrates mammography reporting, cancer risk assessment, and patient tracking specifically for military health facilities.
What is the significance of the contract with the DHA?
This contract, valued at $7.3 million, aims to modernize breast cancer screening for military personnel and their families using cutting-edge technology.
How does Patient Hub™ improve patient care?
By streamlining workflows, automating processes, and enhancing patient communication, it allows healthcare providers to deliver personalized and timely care.
What is Volpara's mission?
Volpara is committed to saving families from cancer through AI-powered solutions that help understand cancer risk and guide care decisions.
How long has Volpara been working with the Department of Defense?
Volpara’s mammography reporting software has been in use by the Department of Defense since 1990, showcasing a long-standing partnership.
